Best Biopharma CEOs of 2025? It’s a robust list this year

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

In an exceptional year for biotech and pharma, there were so many outstanding CEOs, I couldn’t single out just one for my 2025 Best Biopharma CEO honor.

Here are this year’s winners: 

The dealmakers 

2025 has been the best year for biotechs being acquired by pharma companies since 2019, with nearly $240 billion worth of deals announced or closed through November, according to Stifel.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Individual plans

Group plans

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe